Drug repurposing in kidney disease
- 6 April 2018
- journal article
- review article
- Published by Elsevier BV in Kidney International
- Vol. 94 (1), 40-48
- https://doi.org/10.1016/j.kint.2017.12.026
Abstract
No abstract availableFunding Information
- AstraZeneca Australia
This publication has 104 references indexed in Scilit:
- A nonclassical vitamin D receptor pathway suppresses renal fibrosisJCI Insight, 2013
- Is the Serum Vitamin D Level at the Time of Hospital-Acquired Acute Kidney Injury Diagnosis Associated with Prognosis?PLOS ONE, 2013
- Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis developmentGenome Biology, 2013
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic NephropathyJournal of the American Society of Nephrology, 2011
- Activating AMP-activated protein kinase (AMPK) slows renal cystogenesisProceedings of the National Academy of Sciences of the United States of America, 2011
- The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive ratsCardiovascular Diabetology, 2010
- Avosentan for Overt Diabetic NephropathyJournal of the American Society of Nephrology, 2010
- Enhanced Expression of Janus Kinase–Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic NephropathyDiabetes, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin systemJournal of Hypertension, 2008